273.01
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $273.01, with a volume of 766.93K.
It is up +0.37% in the last 24 hours and up +1.06% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$272.00
Open:
$274.29
24h Volume:
766.93K
Relative Volume:
0.78
Market Cap:
$39.97B
Revenue:
$5.15B
Net Income/Loss:
$1.40B
P/E Ratio:
28.71
EPS:
9.5082
Net Cash Flow:
$1.65B
1W Performance:
-2.97%
1M Performance:
+1.06%
6M Performance:
+27.58%
1Y Performance:
+13.51%
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
273.01 | 39.70B | 5.15B | 1.40B | 1.65B | 9.5082 |
![]()
ISRG
Intuitive Surgical Inc
|
435.73 | 154.00B | 9.15B | 2.63B | 1.99B | 7.1661 |
![]()
BDX
Becton Dickinson Co
|
186.66 | 53.47B | 21.39B | 1.61B | 2.55B | 5.5609 |
![]()
ALC
Alcon Inc
|
72.60 | 35.62B | 10.03B | 1.07B | 1.39B | 2.1549 |
![]()
WST
West Pharmaceutical Services Inc
|
262.47 | 18.82B | 2.96B | 487.70M | 344.00M | 6.6758 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-18-25 | Initiated | Citigroup | Buy |
Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-19-25 | Initiated | Morgan Stanley | Overweight |
Jan-16-25 | Initiated | Goldman | Buy |
Jan-10-25 | Initiated | Piper Sandler | Neutral |
Dec-13-24 | Initiated | Stifel | Hold |
Sep-24-24 | Initiated | Robert W. Baird | Outperform |
Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Sep-04-24 | Downgrade | Needham | Buy → Hold |
Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Sep-06-23 | Upgrade | Needham | Hold → Buy |
Sep-05-23 | Downgrade | UBS | Buy → Neutral |
Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
May-23-23 | Initiated | UBS | Buy |
Apr-14-23 | Initiated | Mizuho | Buy |
Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
Oct-12-22 | Initiated | Jefferies | Hold |
Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Apr-06-22 | Initiated | Wolfe Research | Outperform |
Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
Aug-02-21 | Downgrade | Needham | Buy → Hold |
Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
Jun-22-21 | Initiated | Robert W. Baird | Neutral |
Jun-21-21 | Reiterated | Needham | Buy |
Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
May-11-21 | Upgrade | Citigroup | Neutral → Buy |
Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
Mar-16-21 | Upgrade | Needham | Hold → Buy |
Nov-02-20 | Upgrade | UBS | Neutral → Buy |
Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-03-20 | Initiated | CLSA | Underperform |
Jan-31-20 | Downgrade | UBS | Buy → Neutral |
Jan-10-20 | Initiated | Oppenheimer | Perform |
Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
Jul-29-19 | Upgrade | UBS | Neutral → Buy |
Jul-16-19 | Downgrade | UBS | Buy → Neutral |
May-06-19 | Upgrade | UBS | Neutral → Buy |
Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Sleep Apnea Devices MarketGlobal Forecast to 2032, Featuring ResMed, Koninklijke Philips N.V., Fisher & Paykel Healthcare, Alongside Emerging Players Such as Inspire Medical Systems and SomnoMedResearchandmarkets.Com - The AI Journal
ResMed Inc. stock trend forecastBuy Signal & Stock Portfolio Risk Management - newser.com
What recovery options are there for ResMed Inc.2025 Institutional Moves & Free Daily Entry Point Trade Alerts - newser.com
Wells Fargo Initiates Coverage on ResMed (RMD) with Equal-Weight Rating | RMD Stock News - GuruFocus
Is ResMed Inc. stock oversold or undervaluedJuly 2025 Price Swings & Short-Term Swing Trade Alerts - newser.com
Comparing ResMed Inc. in custom built stock radars2025 Earnings Surprises & Capital Efficiency Focused Strategies - newser.com
Zacks.com featured highlights include ResMed, Safran, Pentair, Casey's and Leonardo - Yahoo Finance
Vanguard Personalized Indexing Management LLC Grows Position in ResMed Inc. $RMD - MarketBeat
US Bancorp DE Cuts Position in ResMed Inc. $RMD - MarketBeat
ResMed (RMD): Exploring Valuation After Recent Share Price Pullback - Yahoo Finance
Why ResMed Inc. (RME) stock remains stable2025 Momentum Check & Weekly Chart Analysis and Guides - newser.com
Why ResMed Inc. is moving todayPortfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
Is ResMed Fairly Priced After Recent Patent Dispute Settlement in 2025? - Yahoo
Historical volatility pattern of ResMed Inc. visualizedMarket Activity Report & Low Risk Entry Point Guides - newser.com
Board of the Pension Protection Fund Has $619,000 Holdings in ResMed Inc. $RMD - MarketBeat
Is ResMed Inc. stock entering bullish territoryWeekly Gains Summary & Verified Entry Point Signals - newser.com
Aberdeen Group plc Decreases Holdings in ResMed Inc. $RMD - MarketBeat
Callan Family Office LLC Increases Stock Position in ResMed Inc. $RMD - MarketBeat
L. Roy Papp & Associates LLP Grows Stake in ResMed Inc. $RMD - MarketBeat
Inspire Investing LLC Lowers Position in ResMed Inc. $RMD - MarketBeat
Lindenwold Advisors INC Invests $2.13 Million in ResMed Inc. $RMD - MarketBeat
Triodos Investment Management BV Lowers Holdings in ResMed Inc. $RMD - MarketBeat
How supply shortages influence ResMed Inc. (Common Stock) (RMEA) stockTrade Exit Report & Fast Exit Strategy with Risk Control - newser.com
Michael Farrell Sells 8,009 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - 富途牛牛
Blair William & Co. IL Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
What hedge fund moves indicate for ResMed Inc. (Common Stock) (RMEA) stock2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com
What margin trends mean for ResMed Inc. stockJuly 2025 Summary & Community Verified Swing Trade Signals - newser.com
What earnings revisions data tells us about ResMed Inc.Dividend Hike & Safe Capital Growth Tips - newser.com
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025 - GlobeNewswire
Resmed Scheduled to Release Q1 Fiscal Year 2026 Financial Results on October 30, 2025 - Quiver Quantitative
Resmed CEO Farrell sells $2.26m in shares By Investing.com - Investing.com Nigeria
Resmed CEO Farrell sells $2.26m in shares - Investing.com India
ResMed Insider Sold Shares Worth $2,265,332, According to a Recent SEC Filing - MarketScreener
ResMed’s General Counsel Executes Stock Disposal Under Rule 10b5-1 Plan - MSN
ResMed CFO Reports Changes in Stock Ownership - MSN
Why retail investors favor ResMed Inc. stockMarket Rally & Smart Investment Allocation Tips - newser.com
How ResMed Inc. stock reacts to job market data2025 Geopolitical Influence & Daily Chart Pattern Signals - newser.com
Will breakout in ResMed Inc. lead to full recovery2025 Sector Review & Weekly High Conviction Ideas - newser.com
Will ResMed Inc. stock sustain dividend payoutsJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - newser.com
Does ResMed Inc. (RME) stock trade below intrinsic valueJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
ResMed (NYSE:RMD) Earns Buy (B-) Rating from Weiss Ratings - MarketBeat
Quantitative breakdown of ResMed Inc. recent moveWeekly Loss Report & Consistent Return Strategy Ideas - newser.com
Can ResMed Inc. stock sustain revenue momentumWeekly Trade Recap & Safe Capital Preservation Plans - newser.com
Kidder Stephen W Takes $245,000 Position in ResMed Inc. $RMD - MarketBeat
KLP Kapitalforvaltning AS Boosts Stake in ResMed Inc. $RMD - MarketBeat
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Saudi Arabia $5.94 Bn Sleep Apnea Devices Market Trends, Competition, Forecast & Opportunities, 2030F Featuring ResMed, Philips, Invacare, Itamar Medical, and Nihon Kohden - Yahoo Finance
SGL Investment Advisors Inc. Sells 1,461 Shares of ResMed Inc. $RMD - MarketBeat
What to Expect From ResMed's Next Quarterly Earnings Report - Yahoo Finance
TriaGen Wealth Management LLC Invests $4.03 Million in ResMed Inc. $RMD - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Resmed Inc Stock (RMD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Farrell Michael J. | Chief Executive Officer |
Oct 07 '25 |
Sale |
282.85 |
8,009 |
2,265,332 |
467,792 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):